Moderna (MRNA) Stock: Bernstein Holds Market Perform Rating After Earnings

TLDR Moderna posted Q3 revenue of $1.02 billion, beating estimates but down year-over-year, with a $200 million net loss and reduced 2025 guidance. The biotech firm ended its CMV vaccine program after efficacy issues, marking a pipeline setback for post-COVID diversification plans. Cost cuts in COGS and R&D came in below forecasts, helping Moderna beat [...]

The post Moderna (MRNA) Stock: Bernstein Holds Market Perform Rating After Earnings appeared first on Blockonomi.